The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.Darzalex Faspro is the first and only approved treatment for high-risk smoldering multiple myeloma (HR-SMM), enabling earlier intervention before the disease progresses to active multiple myeloma.Smoldering multiple myeloma is an asymptomatic (no signs or symptoms) precursor state of active myeloma.FDA approval is based on findings fr ...